Abstract
Polymorphisms of human Fc receptors (FcRs) have been described that are associated with the development or progression of autoimmune diseases. The FcR polymorphisms affect the affinity with which FcRs interact with immunoglobulin molecules. Intravenous immunoglobulin is administered as therapy for many autoimmune diseases and might exert its effects by interacting with FcRs. Thus, FcR polymorphisms might influence the efficacy of intravenous immunoglobulin therapy for patients with certain autoimmune diseases. In this article we review FcR polymorphisms in relation to autoimmune diseases for which intravenous immunoglobulin is used therapeutically.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
-
Review
MeSH terms
-
Autoimmune Diseases / genetics*
-
Autoimmune Diseases / immunology
-
Autoimmune Diseases / therapy
-
Granulomatosis with Polyangiitis / genetics
-
Granulomatosis with Polyangiitis / immunology
-
Granulomatosis with Polyangiitis / therapy
-
Guillain-Barre Syndrome / genetics
-
Guillain-Barre Syndrome / immunology
-
Guillain-Barre Syndrome / therapy
-
Humans
-
Immunoglobulins, Intravenous / pharmacology
-
Immunoglobulins, Intravenous / therapeutic use*
-
Lupus Erythematosus, Systemic / genetics
-
Lupus Erythematosus, Systemic / immunology
-
Lupus Erythematosus, Systemic / therapy
-
Polymorphism, Genetic*
-
Purpura, Thrombocytopenic, Idiopathic / genetics
-
Purpura, Thrombocytopenic, Idiopathic / immunology
-
Purpura, Thrombocytopenic, Idiopathic / therapy
-
Receptors, IgG / genetics*
Substances
-
Immunoglobulins, Intravenous
-
Receptors, IgG